| 9.75 -0.04 (-0.41%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.88 | 1-year : | 13.22 |
| Resists | First : | 10.17 | Second : | 11.31 |
| Pivot price | 9.75 |
|||
| Supports | First : | 8.31 | Second : | 6.92 |
| MAs | MA(5) : | 9.81 |
MA(20) : | 9.67 |
| MA(100) : | 7.39 |
MA(250) : | 4.5 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 38.6 |
D(3) : | 42.5 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 11.31 | Low : | 1.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SERA ] has closed above bottom band by 50.0%. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.81 - 9.86 | 9.86 - 9.91 |
| Low: | 9.36 - 9.42 | 9.42 - 9.48 |
| Close: | 9.64 - 9.73 | 9.73 - 9.83 |
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Tue, 16 Apr 2024
Perigon Wealth Management LLC Makes New $509,000 Investment in Sera Prognostics, Inc. (NASDAQ:SERA) - MarketBeat
Sat, 13 Apr 2024
Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Update - MarketBeat
Thu, 28 Mar 2024
Sera prognostics CSO sells over $727k in company stock - Investing.com
Mon, 25 Mar 2024
Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Sun, 24 Mar 2024
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health (NASDAQ:SERA) - Seeking Alpha
Fri, 22 Mar 2024
Sera Prognostics' PreTRM Test Faces Regulatory Risks: The Financial Implications of Potential FDA Hurdles ... - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 1.699e+007 (%) |
| Held by Institutions | 18.1 (%) |
| Shares Short | 107 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.892e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 580.4 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 306000 % |
| Gross Profit (p.s.) | -24.77 |
| Sales Per Share | -28.77 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.34 |
| Price to Cash Flow | 6.57 |
| Dividend | 0 |
| Forward Dividend | 198630 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|